down arrow

SAB Biotherapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US78397T2024
USD
3.80
0.16 (4.4%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.653.92

52 Week

1.006.60
Valuation
Technical
Day's Volume

CASH

207.59 k

Shareholding (Mar 2025)

FII

5.17%

Held by 7 FIIs

DII

90.64%

Held by 5 DIIs

Promoter

0.00%

How big is SAB Biotherapeutics, Inc.?

22-Jun-2025

As of Jun 18, SAB Biotherapeutics, Inc. has a market capitalization of 16.54 million, with net sales of 0.37 million and a net profit of -34.28 million over the latest four quarters. The company reported shareholder's funds of 25.97 million and total assets of 46.06 million as of Dec 24.

Market Cap: As of Jun 18, SAB Biotherapeutics, Inc. has a market capitalization of 16.54 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.37 million and a net profit of -34.28 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 25.97 million and total assets of 46.06 million.

Read More

What does SAB Biotherapeutics, Inc. do?

22-Jun-2025

SAB Biotherapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $16.54 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -183.22%.

Overview: SAB Biotherapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025). Market cap: USD 16.54 Million (Micro Cap).<BR><BR>Key Metrics: P/E: NA (Loss Making), Industry P/E: NA, Dividend Yield: 0.00%, Debt Equity: -0.55, Return on Equity: -183.22%, Price to Book: 0.77.<BR><BR>Contact Details: Not available.

Read More

Is SAB Biotherapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of May 9, 2025, SAB Biotherapeutics, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial ratios and a year-to-date return of -53.61%, significantly underperforming the S&P 500.

As of 9 May 2025, the valuation grade for SAB Biotherapeutics, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently assessed as overvalued, given its negative financial ratios and lack of profitability. Key ratios include a Price to Book Value of 0.79, an EV to EBIT of -0.12, and an EV to EBITDA of -0.13, all of which reflect the company's struggles in generating positive earnings.<BR><BR>In comparison to its peers, SAB Biotherapeutics shows a less favorable position, with companies like Quince Therapeutics, Inc. and VistaGen Therapeutics, Inc. also classified as does not qualify, but with more negative valuations of -1.6083 and -1.4589 respectively. The company's performance has been particularly poor, with a year-to-date return of -53.61%, significantly underperforming the S&P 500, which has returned 2.44% in the same period. This underperformance, combined with the negative financial metrics, reinforces the conclusion that SAB Biotherapeutics is overvalued in the current market.

Read More

Is SAB Biotherapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, SAB Biotherapeutics shows a mildly bullish technical trend supported by strong weekly indicators, despite mixed signals in the longer term and underperformance year-to-date.

As of 11 September 2025, the technical trend has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the Bollinger Bands are bullish on both weekly and monthly time frames, supporting the bullish stance. However, the weekly RSI is bearish, indicating some weakness. The moving averages are bullish on the daily timeframe, while the KST is bullish weekly and mildly bullish monthly. Dow Theory shows a mildly bullish weekly trend but bearish monthly, and the OBV is mildly bullish weekly and mildly bearish monthly.<BR><BR>In terms of multi-period returns, SAB Biotherapeutics has outperformed the S&P 500 over the past week and month, with returns of 31.6% and 27.98% respectively, while it has underperformed year-to-date and over the past year. Overall, the current technical stance is mildly bullish, driven by strong weekly indicators despite some mixed signals in the longer term.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 22 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.40

stock-summary
Return on Equity

-325.72%

stock-summary
Price to Book

1.83

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-10 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
63.79%
0%
63.79%
6 Months
104.3%
0%
104.3%
1 Year
29.69%
0%
29.69%
2 Years
-59.57%
0%
-59.57%
3 Years
236.28%
0%
236.28%
4 Years
-96.15%
0%
-96.15%
5 Years
0%
0%
0.0%

SAB Biotherapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is SAB Biotherapeutics, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the Bollinger Bands are bullish on both weekly and monthly time frames, supporting the bullish stance. However, the weekly RSI is bearish, indicating some weakness. The moving averages are bullish on the daily timeframe, while the KST is bullish weekly and mildly bullish monthly. Dow Theory shows a mildly bullish weekly trend but bearish monthly, and the OBV is mildly bullish weekly and mildly bearish monthly. In terms of multi-period returns, SAB Biotherapeutics has outperformed the S&P 500 over the past week and month, with returns of 31.6% and 27.98% respectively, while it has underperformed year-to-date and over the past year. Overall, the current technical stance is mildly bullish, driven by strong weekly indicators despite some mixed signals in the longer term....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-0.40%
EBIT Growth (5y)
-309.28%
EBIT to Interest (avg)
-24.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.55
Sales to Capital Employed (avg)
0.13
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
43.13%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.79
EV to EBIT
-0.12
EV to EBITDA
-0.13
EV to Capital Employed
0.52
EV to Sales
5.04
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-438.97%
ROE (Latest)
-183.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 5 Schemes (4.18%)

Foreign Institutions

Held by 7 Foreign Institutions (5.17%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -100.00% vs 200.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -38.36% vs -5.80% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.90",
          "val2": "-9.20",
          "chgp": "3.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "2.20",
          "chgp": "-127.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.10",
          "val2": "-7.30",
          "chgp": "-38.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-38,769.50%",
          "chgp": "3,876.95%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -40.91% vs -90.79% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 19.19% vs -125.67% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.30",
          "val2": "2.20",
          "chgp": "-40.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-38.10",
          "val2": "-34.30",
          "chgp": "-11.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "58.40",
          "val2": "-4.80",
          "chgp": "1,316.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-34.10",
          "val2": "-42.20",
          "chgp": "19.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-32,448.70%",
          "val2": "-17,005.60%",
          "chgp": "-1,544.31%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.30
-100.00%
Operating Profit (PBDIT) excl Other Income
-8.90
-9.20
3.26%
Interest
0.10
0.10
Exceptional Items
-0.60
2.20
-127.27%
Consolidate Net Profit
-10.10
-7.30
-38.36%
Operating Profit Margin (Excl OI)
0.00%
-38,769.50%
3,876.95%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -100.00% vs 200.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -38.36% vs -5.80% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1.30
2.20
-40.91%
Operating Profit (PBDIT) excl Other Income
-38.10
-34.30
-11.08%
Interest
0.30
0.30
Exceptional Items
58.40
-4.80
1,316.67%
Consolidate Net Profit
-34.10
-42.20
19.19%
Operating Profit Margin (Excl OI)
-32,448.70%
-17,005.60%
-1,544.31%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -40.91% vs -90.79% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 19.19% vs -125.67% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About SAB Biotherapeutics, Inc. stock-summary
stock-summary
SAB Biotherapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."